Latest news with #GeoffMeacham
Yahoo
11-06-2025
- Business
- Yahoo
Citi sees Gilead clinical holds as only ‘minor setback'
Citi analyst Geoff Meacham keeps a Buy rating on Gilead (GILD) with a $125 price target after the company announced a clinical hold on its Phase 2 WONDERS trials evaluating the combination of GS-1720 and GS-4182 for once-weekly oral HIV treatment. The hold was initiated due to safety concerns, specifically decreases in CD4+ T-cell and absolute lymphocyte counts observed in a subset of participants receiving the combination therapy, the analyst tells investors in a research note. Citi says the setback impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously anticipated in 2029 or 2030. The hold does not affect Gilead's other ongoing HIV programs, including lenacapavir development for both treatment and prevention including the monthly oral combinations, as no similar lymphocyte or CD4 effects have been observed in these studies, Citi points out. As such, the firm sees the holds as a 'minor setback' and continues to believe that lenacapavir in pre-exposure prophylaxis and expansion of several differentiated lenacapavir combos should offset potential Biktarvy 2028 Inflation Reduction Act negotiations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GILD: Disclaimer & DisclosureReport an Issue FDA placed clinical hold on Gilead HIV treatment trials of GS-1720 Gilead down 2% to $111.14 after FDA placed hold on some HIV trials Gilead Sciences: Strong Market Position and Growth Potential Drive Buy Rating Gilead Sciences' Oncology Advancements: Trodelvy's Potential to Boost Stock Value Gilead Sciences: Promising Pipeline and Strategic Advancements Justify Buy Rating Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
02-06-2025
- Business
- Business Insider
Regeneron price target lowered to $650 from $700 at Citi
Citi analyst Geoff Meacham lowered the firm's price target on Regeneron (REGN) to $650 from $700 and keeps a Buy rating on the shares. The company reported mixed itepekimab Phase 3 COPD results in former smokers, the analyst tells investors in a research note. The firm says that wWhile Aerify-1 met its primary endpoint in both dosing arms, Aerify-2 failed to achieve statistical significance improvement at week 52. While Aerify-1 was positive, the path to approval is unclear, contends Citi. Confident Investing Starts Here:
Yahoo
21-05-2025
- Business
- Yahoo
Citi Maintains a Hold Rating on Pfizer (PFE) Amidst Pricing Policy Headwinds
On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of $25. The analyst acknowledged the strong Q1 2025 performance of the company. However, he remains cautious due to the potential Most Favored Nation (MFN) pricing policy headwinds. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. The Most Favored Nation (MFN) pricing policy is a government initiative in the United States to lower prescription drug prices to ensure that the prices paid by US government programs do not exceed the lowest prices paid by comparable developed countries. This policy has resurfaced under the Trump administration in 2025. The Trump administration argues that this policy will result in US drug prices dropping by 30% to 80%. During the first quarter 2025 earnings call, Dave Denton, CFO of Pfizer Inc. (NYSE:PFE), noted the changes in the IRA Medicare Part D redesign, tempered US revenue. The IRA Medicare Part D is another government initiative aimed at cutting drug prices. Analyst Meacham noted that although the company is actively pursuing opportunities in oncology and cardio-metabolic assets, the market remains overvalued. Thereby requiring a disciplined approach to business development. Moreover, the pricing policy headwinds present challenges that Pfizer Inc. (NYSE:PFE) has to navigate carefully, thereby justifying the Hold rating. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None
Yahoo
21-05-2025
- Business
- Yahoo
Citi Maintains a Hold Rating on Pfizer (PFE) Amidst Pricing Policy Headwinds
On May 21, analyst Geoff Meacham of Citi maintained a Hold rating on Pfizer Inc. (NYSE:PFE), reiterating the price target of $25. The analyst acknowledged the strong Q1 2025 performance of the company. However, he remains cautious due to the potential Most Favored Nation (MFN) pricing policy headwinds. A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution. The Most Favored Nation (MFN) pricing policy is a government initiative in the United States to lower prescription drug prices to ensure that the prices paid by US government programs do not exceed the lowest prices paid by comparable developed countries. This policy has resurfaced under the Trump administration in 2025. The Trump administration argues that this policy will result in US drug prices dropping by 30% to 80%. During the first quarter 2025 earnings call, Dave Denton, CFO of Pfizer Inc. (NYSE:PFE), noted the changes in the IRA Medicare Part D redesign, tempered US revenue. The IRA Medicare Part D is another government initiative aimed at cutting drug prices. Analyst Meacham noted that although the company is actively pursuing opportunities in oncology and cardio-metabolic assets, the market remains overvalued. Thereby requiring a disciplined approach to business development. Moreover, the pricing policy headwinds present challenges that Pfizer Inc. (NYSE:PFE) has to navigate carefully, thereby justifying the Hold rating. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
15-04-2025
- Business
- Globe and Mail
TD Cowen Remains a Hold on Pfizer (PFE)
TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company's shares closed yesterday at $22.12. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Scala covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and AstraZeneca. According to TipRanks, Scala has an average return of 4.2% and a 55.62% success rate on recommended stocks. In addition to TD Cowen, Pfizer also received a Hold from Citi's Geoff Meacham in a report issued today. However, yesterday, Jefferies maintained a Buy rating on Pfizer (NYSE: PFE). Based on Pfizer's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.76 billion and a net profit of $410 million. In comparison, last year the company earned a revenue of $14.25 billion and had a GAAP net loss of $3.34 billion Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock. Last month, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,249.00 shares for a total of $84,373.90.
